Clinical Trials · NCT03361098
DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Amsterdam UMC, location VUmc
- Enrollment
- 65
- Start date
- Sep 2017
- Locations
- 1 site, Netherlands
- Primary endpoint
- Differences in neuronal activity in the central reward and satiety circuits in response to food-related stimuli by BOLD fMRI signal